卡瑞利珠单抗联合射频消融术及FOLFOX方案治疗原发性肝癌疗效研究  

Clinical Efficacy of Camrelizumab Combined with Radiofrequency Ablation and FOLFOX Regimen in the Treatment of Patients with Primary Hepatocellular Carcinoma

作　　者：朱风婷 曾江正[2] 姜靖雯[1] 陈学武[1] 张慧[1] ZHU Fengting;ZENG Jiangzheng;JIANG Jingwen;CHEN Xuewu;ZHANG Hui(Department of Oncology,Hainan Hospital of Traditional Chinese Medicine,Haikou,Hainan,China 570203;Department of Oncology,The First Affiliated Hospital of Hainan Medical College,Haikou,Hainan,China 570102)

机构地区：[1]海南省中医院肿瘤科,海南海口570203 [2]海南医学院第一附属医院肿瘤内科,海南海口570102

出　　处：《中国药业》2021年第15期38-41,共4页China Pharmaceuticals

基　　金：国家自然科学基金[81960549]。

摘　　要：目的探讨卡瑞利珠单抗联合射频消融术及FOLFOX方案治疗原发性肝癌的疗效,以及对患者色素框同源蛋白7(CBX7)、上皮钙黏附素基因蛋白(CDH1)水平的影响。方法选取海南省中医院2019年5月至2020年11月收治的原发性肝癌患者80例,随机分为观察组和对照组,各40例。两组患者均予射频消融术,术后给予FOLFOX方案(奥沙利铂+亚叶酸钙+氟尿嘧啶),观察组患者加用注射用卡瑞利珠单抗。两组患者均以2周为1个治疗周期,连续治疗3个周期。结果治疗过程中,观察组患者自愿退出1例、失访2例,对照组患者调整治疗方案1例、失访1例,均予以剔除。观察组患者的客观缓解率及疾病控制率分别为48.65%和64.86%,显著高于对照组的26.32%和42.11%(P<0.05);治疗后,观察组患者的甲胎蛋白、癌胚抗原、糖类抗原199、CBX7、CDH1水平均显著低于对照组(P<0.05);观察组与对照组不良反应发生率相当(29.73%比23.68%,P>0.05)。结论卡瑞利珠单抗联合射频消融术及FOLFOX方案治疗原发性肝癌近期疗效较好,能降低患者肿瘤标志物水平,减弱CBX7和CDH1表达水平。Objective To investigate the clinical efficacy of camrelizumab combined with radiofrequency ablation and FOLFOX regimen in the treatment of patients with primary hepatocellular carcinoma and its effect on the levels of chromobox homolog 7(CBX7)protein and epithelial-cadherin gene(CDH1)protein.Methods A total of 80 patients with primary hepatocellular carcinoma admitted to the Hainan Hospital of Traditional Chinese Medicine from May 2019 to November 2020 were selected and randomly divided into the observation group and the control group,40 cases in each group.The patients in both groups were treated with radiofrequency ablation,and then they were given FOLFOX regimen(oxaliplatin+calcium folinate+fluorouracil)after the operation,on this basis,the patients in the observation group were additionally treated with camrelizumab.Both groups were treated for three consecutive cycles with two weeks as a treatment cycle.Results During the treatment,one case voluntarily withdrew and two cases lost follow-up in the observation group,while one case adjusted the treatment plan and one case lost follow-up in the control group,all of them were excluded.The objective remission rate(ORR)and disease control rate(DCR)of the observation group were 48.65%and 64.86%respectively,which were significantly higher than 26.32%and 42.11%of the control group(P<0.05).After treatment,the levels of alpha-fetoprotein(AFP),carcinoembryonic antigen(CEA),carbohydrate antigen 199(CA199),CBX7 and CDH1 in the observation group were significantly lower than those in the control group(P<0.05).The incidence of adverse reactions in the observation group was similar to that in the control group(29.73%vs.23.68%,P>0.05).Conclusion Camrelizumab combined with radiofrequency ablation and FOLFOX regimen in the treatment of patients with primary hepatocellular carcinoma can reduce the tumor marker levels and the expression levels of CBX7 and CDH1.

关 键 词：原发性肝癌 卡瑞利珠单抗 射频消融术 化学治疗 FOLFOX方案 临床疗效 

分 类 号：R969.4[医药卫生—药理学] R979.1[医药卫生—药学]